This company has been marked as potentially delisted and may not be actively trading. Intra-Cellular Therapies (ITCI) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipSustainabilityTrendsBuy This Stock Get the Latest News and Ratings for ITCI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITCI Analyst Ratings Over TimeTypeCurrent Forecast9/18/24 to 9/18/251 Month Ago8/19/24 to 8/19/253 Months Ago6/20/24 to 6/20/251 Year Ago9/19/23 to 9/18/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)2 Buy rating(s)10 Buy rating(s)Hold8 Hold rating(s)8 Hold rating(s)10 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$118.00$118.00$109.70$96.58Forecasted Upside-10.52% Downside-10.52% Downside-16.81% Downside29.29% UpsideConsensus RatingHoldHoldHoldModerate Buy ITCI Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ITCI Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Intra-Cellular Therapies Stock vs. The CompetitionTypeIntra-Cellular TherapiesMedical CompaniesS&P 500Consensus Rating Score 2.20 2.78 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside-10.52% Downside18,064.71% Upside11.43% UpsideNews Sentiment RatingNeutral NewsSee Recent ITCI NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails4/2/2025Cantor Fitzgerald4 of 5 starsC. Duncan Not RatedReiterated RatingNeutral$132.00 ➝ $132.00+0.07%2/24/2025Mizuho3 of 5 starsGraig Suvannavejh4 of 5 starsDowngradeOutperform ➝ Neutral$140.00 ➝ $132.00+2.64%2/21/2025Needham & Company LLC2 of 5 starsA. Fadia Not RatedReiterated RatingHold1/31/2025Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSumant KulkarniSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$119.00 ➝ $132.00+3.94%1/22/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian AbrahamsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$108.00 ➝ $132.00+3.61%1/14/2025Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid AmsellemSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$107.00 ➝ $132.00+3.89%1/13/2025Leerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingM. GoodmanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold1/13/2025Baird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJ. BeattySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold11/4/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOverweight$81.00 ➝ $89.00+2.84%10/11/2024Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOverweight$92.00 ➝ $95.00+25.02% Get the Latest News and Ratings for ITCI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. 8/8/2024UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingA. VermaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$83.00 ➝ $79.00+7.61%8/8/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetNeutral$77.00 ➝ $74.00+0.50%4/17/2024TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$80.00 ➝ $90.00+15.05%4/17/2024Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOutperform$83.00 ➝ $103.00+31.66%4/17/2024Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$82.00 ➝ $91.00+16.32%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:32 AM ET. ITCI Forecast - Frequently Asked Questions What is Intra-Cellular Therapies' forecast for 2025? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Intra-Cellular Therapies is $118.00, with a high forecast of $132.00 and a low forecast of $89.00. Should I buy or sell Intra-Cellular Therapies stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ITCI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITCI, but not buy additional shares or sell existing shares. Does Intra-Cellular Therapies's stock price have much downside? According to analysts, Intra-Cellular Therapies's stock has a predicted downside of -10.52% based on their 12-month stock forecasts. Do Wall Street analysts like Intra-Cellular Therapies more than its competitors? Analysts like Intra-Cellular Therapies less than other "medical" companies. The consensus rating for Intra-Cellular Therapies is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ITCI compares to other companies. Stock Forecasts and Research Tools Related Companies TAK Stock Forecast ARGX Stock Forecast ONC Stock Forecast INSM Stock Forecast BNTX Stock Forecast TEVA Stock Forecast GMAB Stock Forecast SMMT Stock Forecast RDY Stock Forecast ASND Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:ITCI) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITCI Stock Alerts